TMRC, Syros deal

TMRC granted Syros exclusive rights to develop and commercialize tamibarotene in North America and Europe to treat cancer. Syros said it discovered a biomarker associated with retinoic acid receptor alpha (RARA) dependency in subsets of acute myelogenous leukemia and breast cancer patients who may respond to RARA agonist therapy. The compound is a synthetic retinoid targeting RARA. ...